Analysts have been eager to weigh in on the Healthcare sector with new ratings on Akoya Biosciences (AKYA – Research Report), Paycor HCM (PYCR – Research Report) and ADC Therapeutics (ADCT – Research Report).
Akoya Biosciences (AKYA)
In a report released today, Kyle Mikson CFA from Canaccord Genuity maintained a Buy rating on Akoya Biosciences, with a price target of $14.00. The company’s shares closed last Wednesday at $3.76, close to its 52-week low of $3.04.
According to TipRanks.com, CFA has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Akoya Biosciences with a $10.00 average price target.
See the top stocks recommended by analysts >>
Paycor HCM (PYCR)
In a report released today, Scott Berg from Needham maintained a Buy rating on Paycor HCM, with a price target of $42.00. The company’s shares closed last Wednesday at $17.85, close to its 52-week low of $17.13.
According to TipRanks.com, Berg is a 3-star analyst with an average return of
Currently, the analyst consensus on Paycor HCM is a Moderate Buy with an average price target of $27.00, a 51.3% upside from current levels. In a report issued on October 30, Truist Financial also maintained a Buy rating on the stock with a $33.00 price target.
ADC Therapeutics (ADCT)
ADC Therapeutics received a Hold rating from TD Cowen analyst Boris Peaker today. The company’s shares closed last Wednesday at $0.60, close to its 52-week low of $0.59.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of
ADC Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AKYA:
- Akoya Reports Record Revenue in the Third Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya Biosciences to showcase spatial biology 2.0 solutions
- Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023
- Akoya Biosciences price target lowered to $8 from $15 at Morgan Stanley
- Akoya Biosciences announces publication on ultrahigh-plex spatial phenotyping
